Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003615 · ClinicalTrials.gov registry record · Phase 2
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00003615 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 77 participants.
The verdict
NCT00003615, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
RATIONALE: Immunotoxins such as denileukin diftitox can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of denileukin diftitox in treating patients who have non-Hodgkin's lymphoma that has not responded to previous treatment.
Interventions
- BIOLOGICAL denileukin diftitox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 1999-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003615
The ClinicalTrials.gov registry entry for NCT00003615 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which denileukin diftitox is the first listed.
NCT00003615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003615 about?
NCT00003615 is a clinical study titled "Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma". RATIONALE: Immunotoxins such as denileukin diftitox can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of denileukin diftitox in treating patients who have non-Hodgkin'...
What is the current status of trial NCT00003615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 1999-05-20.
What interventions are being tested in trial NCT00003615?
The interventions under investigation include: denileukin diftitox (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003615?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.